“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer - Episode 3

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

, , ,

Challenges for patients diagnosed with metastatic HER2+ breast cancer and recent FDA approved-therapies for the third-line setting are reviewed.